Literature DB >> 29973404

The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.

Colin Havenar-Daughton1,2, Anita Sarkar2,3,4, Daniel W Kulp2,3,5,6, Laura Toy7,2, Xiaozhen Hu2,3,5, Isaiah Deresa7, Oleksandr Kalyuzhniy2,3,5, Kirti Kaushik7,2, Amit A Upadhyay8, Sergey Menis2,3,5, Elise Landais3,5, Liwei Cao2,5,9, Jolene K Diedrich9, Sonu Kumar2,3,4, Torben Schiffner2,3,5, Samantha M Reiss7,2, Grégory Seumois7, John R Yates9, James C Paulson2,5,9, Steven E Bosinger8, Ian A Wilson2,3,4,10, William R Schief2,3,5,11, Shane Crotty1,2,12.   

Abstract

Traditional vaccine development to prevent some of the worst current pandemic diseases has been unsuccessful so far. Germline-targeting immunogens have potential to prime protective antibodies (Abs) via more targeted immune responses. Success of germline-targeting vaccines in humans will depend on the composition of the human naive B cell repertoire, including the frequencies and affinities of epitope-specific B cells. However, the human naive B cell repertoire remains largely undefined. Assessment of antigen-specific human naive B cells among hundreds of millions of B cells from multiple donors may be used as pre-phase 1 ex vivo human testing to potentially forecast B cell and Ab responses to new vaccine designs. VRC01 is an HIV broadly neutralizing Ab (bnAb) against the envelope CD4-binding site (CD4bs). We characterized naive human B cells recognizing eOD-GT8, a germline-targeting HIV-1 vaccine candidate immunogen designed to prime VRC01-class Abs. Several distinct subclasses of VRC01-class naive B cells were identified, sharing sequence characteristics with inferred precursors of known bnAbs VRC01, VRC23, PCIN63, and N6. Multiple naive B cell clones exactly matched mature VRC01-class bnAb L-CDR3 sequences. Non-VRC01-class B cells were also characterized, revealing recurrent public light chain sequences. Unexpectedly, we also identified naive B cells related to the IOMA-class CD4bs bnAb. These different subclasses within the human repertoire had strong initial affinities (KD) to the immunogen, up to 13 nM, and represent encouraging indications that multiple independent pathways may exist for vaccine-elicited VRC01-class bnAb development in most individuals. The frequencies of these distinct eOD-GT8 B cell specificities give insights into antigen-specific compositional features of the human naive B cell repertoire and provide actionable information for vaccine design and advancement.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29973404      PMCID: PMC6145074          DOI: 10.1126/scitranslmed.aat0381

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  56 in total

Review 1.  Germinal centers.

Authors:  Gabriel D Victora; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

2.  Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.

Authors:  Xueling Wu; Zhenhai Zhang; Chaim A Schramm; M Gordon Joyce; Young Do Kwon; Tongqing Zhou; Zizhang Sheng; Baoshan Zhang; Sijy O'Dell; Krisha McKee; Ivelin S Georgiev; Gwo-Yu Chuang; Nancy S Longo; Rebecca M Lynch; Kevin O Saunders; Cinque Soto; Sanjay Srivatsan; Yongping Yang; Robert T Bailer; Mark K Louder; James C Mullikin; Mark Connors; Peter D Kwong; John R Mascola; Lawrence Shapiro
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

3.  Divergent human populations show extensive shared IGK rearrangements in peripheral blood B cells.

Authors:  Katherine Jean Louise Jackson; Yan Wang; Bruno A Gaeta; William Pomat; Peter Siba; Janet Rimmer; William A Sewell; Andrew M Collins
Journal:  Immunogenetics       Date:  2011-07-26       Impact factor: 2.846

4.  Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

Authors:  Harry B Gristick; Lotta von Boehmer; Anthony P West; Michael Schamber; Anna Gazumyan; Jovana Golijanin; Michael S Seaman; Gerd Fätkenheuer; Florian Klein; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Nat Struct Mol Biol       Date:  2016-09-12       Impact factor: 15.369

Review 5.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

6.  Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Authors:  Ron Diskin; Johannes F Scheid; Paola M Marcovecchio; Anthony P West; Florian Klein; Han Gao; Priyanthi N P Gnanapragasam; Alexander Abadir; Michael S Seaman; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Science       Date:  2011-10-27       Impact factor: 47.728

7.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

8.  Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

Authors:  Joseph G Jardine; Devin Sok; Jean-Philippe Julien; Bryan Briney; Anita Sarkar; Chi-Hui Liang; Erin A Scherer; Carole J Henry Dunand; Yumiko Adachi; Devan Diwanji; Jessica Hsueh; Meaghan Jones; Oleksandr Kalyuzhniy; Michael Kubitz; Skye Spencer; Matthias Pauthner; Karen L Saye-Francisco; Fabian Sesterhenn; Patrick C Wilson; Denise M Galloway; Robyn L Stanfield; Ian A Wilson; Dennis R Burton; William R Schief
Journal:  PLoS Pathog       Date:  2016-08-25       Impact factor: 6.823

9.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  51 in total

Review 1.  Rationalizing Random Walks: Replicating Protective Antibody Trajectories.

Authors:  Jennifer L Remmel; Margaret E Ackerman
Journal:  Trends Immunol       Date:  2021-01-26       Impact factor: 16.687

2.  A Potent anti-Simian Immunodeficiency Virus Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Rhesus Macaques.

Authors:  Saori Matsuoka; Takeo Kuwata; Hiroshi Ishii; Tsuyoshi Sekizuka; Makoto Kuroda; Masato Sano; Midori Okazaki; Hiroyuki Yamamoto; Mikiko Shimizu; Shuzo Matsushita; Yohei Seki; Akatsuki Saito; Hiromi Sakawaki; Vanessa M Hirsch; Tomoyuki Miura; Hirofumi Akari; Tetsuro Matano
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

3.  HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.

Authors:  Yu-Ru Lin; K Rachael Parks; Connor Weidle; Anika S Naidu; Arineh Khechaduri; Andrew O Riker; Brittany Takushi; Jung-Ho Chun; Andrew J Borst; David Veesler; Andrew Stuart; Parul Agrawal; Matthew Gray; Marie Pancera; Po-Ssu Huang; Leonidas Stamatatos
Journal:  Immunity       Date:  2020-10-13       Impact factor: 31.745

4.  A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Authors:  Jon M Steichen; Ying-Cing Lin; Colin Havenar-Daughton; Simone Pecetta; Gabriel Ozorowski; Jordan R Willis; Laura Toy; Devin Sok; Alessia Liguori; Sven Kratochvil; Jonathan L Torres; Oleksandr Kalyuzhniy; Eleonora Melzi; Daniel W Kulp; Sebastian Raemisch; Xiaozhen Hu; Steffen M Bernard; Erik Georgeson; Nicole Phelps; Yumiko Adachi; Michael Kubitz; Elise Landais; Jeffrey Umotoy; Amanda Robinson; Bryan Briney; Ian A Wilson; Dennis R Burton; Andrew B Ward; Shane Crotty; Facundo D Batista; William R Schief
Journal:  Science       Date:  2019-10-31       Impact factor: 47.728

5.  Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.

Authors:  Wilton B Williams; R Ryan Meyerhoff; R J Edwards; Hui Li; Kartik Manne; Nathan I Nicely; Rory Henderson; Ye Zhou; Katarzyna Janowska; Katayoun Mansouri; Sophie Gobeil; Tyler Evangelous; Bhavna Hora; Madison Berry; A Yousef Abuahmad; Jordan Sprenz; Margaret Deyton; Victoria Stalls; Megan Kopp; Allen L Hsu; Mario J Borgnia; Guillaume B E Stewart-Jones; Matthew S Lee; Naomi Bronkema; M Anthony Moody; Kevin Wiehe; Todd Bradley; S Munir Alam; Robert J Parks; Andrew Foulger; Thomas Oguin; Gregory D Sempowski; Mattia Bonsignori; Celia C LaBranche; David C Montefiori; Michael Seaman; Sampa Santra; John Perfect; Joseph R Francica; Geoffrey M Lynn; Baptiste Aussedat; William E Walkowicz; Richard Laga; Garnett Kelsoe; Kevin O Saunders; Daniela Fera; Peter D Kwong; Robert A Seder; Alberto Bartesaghi; George M Shaw; Priyamvada Acharya; Barton F Haynes
Journal:  Cell       Date:  2021-05-20       Impact factor: 41.582

6.  Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies.

Authors:  Emilie Seydoux; Yu-Hsin Wan; Junli Feng; Abigail Wall; Safia Aljedani; Leah J Homad; Anna J MacCamy; Connor Weidle; Matthew D Gray; Lauren Brumage; Justin J Taylor; Marie Pancera; Leonidas Stamatatos; Andrew T McGuire
Journal:  Cell Rep       Date:  2021-05-04       Impact factor: 9.423

7.  Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

Authors:  Shelly J Krebs; Young D Kwon; Chaim A Schramm; William H Law; Gina Donofrio; Kenneth H Zhou; Syna Gift; Vincent Dussupt; Ivelin S Georgiev; Sebastian Schätzle; Jonathan R McDaniel; Yen-Ting Lai; Mallika Sastry; Baoshan Zhang; Marissa C Jarosinski; Amy Ransier; Agnes L Chenine; Mangaiarkarasi Asokan; Robert T Bailer; Meera Bose; Alberto Cagigi; Evan M Cale; Gwo-Yu Chuang; Samuel Darko; Jefferson I Driscoll; Aliaksandr Druz; Jason Gorman; Farida Laboune; Mark K Louder; Krisha McKee; Letzibeth Mendez; M Anthony Moody; Anne Marie O'Sullivan; Christopher Owen; Dongjun Peng; Reda Rawi; Eric Sanders-Buell; Chen-Hsiang Shen; Andrea R Shiakolas; Tyler Stephens; Yaroslav Tsybovsky; Courtney Tucker; Raffaello Verardi; Keyun Wang; Jing Zhou; Tongqing Zhou; George Georgiou; S Munir Alam; Barton F Haynes; Morgane Rolland; Gary R Matyas; Victoria R Polonis; Adrian B McDermott; Daniel C Douek; Lawrence Shapiro; Sodsai Tovanabutra; Nelson L Michael; John R Mascola; Merlin L Robb; Peter D Kwong; Nicole A Doria-Rose
Journal:  Immunity       Date:  2019-03-12       Impact factor: 43.474

Review 8.  HIV vaccinology: 2021 update.

Authors:  Jeong Hyun Lee; Shane Crotty
Journal:  Semin Immunol       Date:  2021-07-14       Impact factor: 10.671

Review 9.  Recent progress in broadly neutralizing antibodies to HIV.

Authors:  Devin Sok; Dennis R Burton
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 31.250

Review 10.  Factors in B cell competition and immunodominance.

Authors:  Robert K Abbott; Shane Crotty
Journal:  Immunol Rev       Date:  2020-06-01       Impact factor: 10.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.